Covalon Technologies Ltd. · TSXV:COV
Covalon Technologies — Shareholder Meeting (March 2025)
24 slides from Covalon Technologies's shareholder meeting presentation, Mar 19, 2025
Slide 1: 2024 Annual Shareholders Meeting
TSX-V: COV OTCQX: CVALF info@covalon.com 2024 Annual Shareholders Meeting March 19, 2025 Brent Ashton Chief Executive Officer www.covalon.com helping the most vulnerable patients 1 have a better chance at healing
Slide 2: Management Presentation
Management Presentation Brent Ashton Chief Executive Officer TSX-V: COV OTCQX: CVALF info@covalon.com
Slide 3: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Certain statements included in this presentation may be considered forward-looking statements. These forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “plan”, “estimate”, “e
Slide 4: Covalon Technologies Ltd.
Covalon Technologies Ltd. We provide innovative and cost-effective healthcare solutions that help prevent infection, reduce pain, and promote healing 12
Slide 5: Patients shouldn't have to suffer due to:
Patients shouldn’t have to suffer due to : Blood Stream Infections Medical Adhesive Related Skin Injury Surgical Site Infections Chronic Wounds That Don’t Heal 13
Slide 6: Patients shouldn't have to suffer due to:
Patients shouldn’t have to suffer due to : Blood Stream Infections Medical Adhesive Related Skin Injury These complications affect millions of patients every year and can lead to: Intense pain and suffering Lower quality of life Mental health challenges such as Surgical Site Infections Chronic Wound
Slide 7: Dennis Woo, RN – Interventional Vascular Access Specialist
Dennis Woo, RN – Interventional Vascular Access Specialist 15
Slide 8: Video clip
Please click here to access video clip within your browser
Slide 9: No one better suited to address these critical quality metrics
Covalon Solutions Directly Address Customers’ Areas of Focus No one better suited to address these critical quality metrics than Covalon ! 17
Slide 10: Covalon Investment Thesis
Covalon Investment Thesis Solving sizable customer Favorable trends and Strong underlying financials challenges with differentiated, competitive environment protected products Significant product and Growth acceleration led by geographical growth experienced leadership potential team 18
Slide 11: Covalon - Advanced Wound Care: The Clinical Challenge
Covalon - Advanced Wound Care The Clinical Challenge Growing number of chronic wounds (affect 11 Million patients in the US with a cost to treat of $28 Billion)1 High rates of infection (~45%) stall healing and lead to significant complications2 Without proper treatment – can lead to reduced quality
Slide 12: Covalon - Advanced Wound Care: The Covalon Solution
Covalon - Advanced Wound Care The Covalon Solution US Market Performance Our goal = accelerate wound healing to US Market Covalon US CAGR allow patients to get back to their normal, Growth1 (FY‘21 – FY’24) healthy lives 8% - 10% > 30% Before After Covalon’s Largest Competitors: How We Win Absorbs 20
Slide 13: Covalon - Vascular Access and Surgical Consumables: The Clinical Challenge
•. 2015 Nov-Dec;42(6):589-98. Covalon - Vascular Access and Surgical Consumables The Clinical Challenge Catheter Related Blood Stream Infections affect more than 500,000 Americans each year, kill more than 50,000 and cost health systems billions1 Surgical Site Infections affect more than 100,000 Ame
Slide 14: Covalon - Vascular Access and Surgical Consumables: US Market Performance
Covalon - Vascular Access and Surgical Consumables Covalon Solutions US Market Performance Only catheter line US Market Covalon US CAGR guard to protect Growth1 (FY‘21 – FY’24 against gross contamination 5% - 7% 50% + Covalon’s Largest Competitors Dual-antimicrobial dressings (IV Clear® and SurgiCle
Slide 15: US Vascular Access and Surgical Consumables – Strong Focus Driving Outstanding Growth
US Vascular Access and Surgical Consumables – Strong Focus Driving Outstanding Growth RETAIN GROW EXISTING ADD NEW 98% retention of our 55% revenue growth from Acquired 66 new hospital Top 50 FY’23 hospital our Top 50 FY’23 hospital customers in FY’24 customers customers 23
Slide 16: Highlights – Past 12 Months
Highlights – Past 12 Months VALGuard® system-wide use Significant Market Development >50%+ FY’24 revenue growth at approval at a US top 5 Integrated advancement – clinical evidence, half of the 30 largest Children’s Delivery Network KOL relationships Hospitals in the United States Signed new strateg
Slide 17: FY 2024 Financial Outcomes
FY 2024 Financial Outcomes Revenue and Growth Revenue and Growth Full Company US Medical Consumables $35,000 60.0% $30,000 70.0% $30,000 50.0% $25,000 60.0% $25,000 40.0% 30.0% 50.0% • Strong growth – led by $20,000 $20,000 20.0% 40.0% focus on US Product $15,000 $15,000 10.0% 30.0% segment 0.0% $10
Slide 18: FY 2024 Financial Outcomes
FY 2024 Financial Outcomes Net Income Adjusted EBITDA Cash Position $4,840 $4,000 $18,000 $2,670 $4,000 $2,000 $16,000 $2,000 $0 $14,000 2022 2023 2024 $0 $12,000 ($2,000) 2022 2023 2024 ($2,000) $10,000 ($4,000) ($4,461) ($2,682) $8,000 ($6,000) ($4,000) $6,000 ($8,000) ($6,000) ($5,663) ($10,000)
Slide 19: Covalon Focus on Future Growth Acceleration
Covalon Focus on Future Growth Acceleration Accelerate Demand Generation and Grow Revenue Commercial Market Development Innovation and Operational Advancement Business Development Optimization Support Revenue Acceleration and Improve Margins 27
Slide 20: Preventing Complications from Peripheral IV's
Preventing Complications from Peripheral IV’s Rapidly Expanding Market – Covalon Well Positioned For Success Central Lines Peripheral Lines (PIVs, Midlines) (CVCs, PICCs, Ports, etc. ) Clinical Practice Scientific Clinical Guidelines Meetings Surveillance 10 M 250 k 38 k 200 M 360 k 46 k Hospital-On
Slide 21: Covalon Investment Thesis
Covalon Investment Thesis Solving sizable customer Favorable trends and Strong underlying financials challenges with differentiated, competitive environment protected products Significant product and Growth acceleration led by geographical growth experienced leadership potential team 29
Slide 22: Q&A
Q&A 30
Slide 23: Investor Relations Contact Information
Investor Relations Contact Information Brent Ashton Katie Martinovich Chief Executive Officer Interim Chief Financial Officer investors@covalon.com 31
Slide 24: www.covalon.com | info@covalon.com
www.covalon.com I info@covalon.com
Covalon Technologies — Shareholder Meeting (March 2025) on 6ix